Subsequently, the combination of anti-PD-1 and anti-CTLA-4 was approved as a first line therapy for the treatment of patients with unresectable or metastatic melanoma (Larkin et al., 2015; Postow et al., 2015). The gene discussed is PDCD1; the disease is metastatic melanoma.